These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17222199)

  • 1. Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
    Kukreja A; Hutchinson A; Mazumder A; Vesole D; Angitapalli R; Jagannath S; O'connor OA; Dhodapkar MV
    Br J Haematol; 2007 Jan; 136(1):106-10. PubMed ID: 17222199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
    Kelley TW; Alkan S; Srkalovic G; Hsi ED
    Leuk Res; 2004 Aug; 28(8):845-50. PubMed ID: 15203282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
    Subklewe M; Sebelin-Wulf K; Beier C; Lietz A; Mathas S; Dörken B; Pezzutto A
    Hum Immunol; 2007 Mar; 68(3):147-55. PubMed ID: 17349869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
    Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
    Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
    Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
    Bersani F; Taulli R; Accornero P; Morotti A; Miretti S; Crepaldi T; Ponzetto C
    Eur J Cancer; 2008 Apr; 44(6):876-84. PubMed ID: 18342500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade).
    Arpinati M; Chirumbolo G; Nicolini B; Agostinelli C; Rondelli D
    Bone Marrow Transplant; 2009 Feb; 43(3):253-9. PubMed ID: 18806836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Proteasome inhibitors].
    Hatake K; Mishima Y; Terui Y
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bortezomib].
    Simons S; Scheulen ME; Jaehde U
    Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
    [No Abstract]   [Full Text] [Related]  

  • 11. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
    Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspective on the current use of bortezomib in multiple myeloma.
    San-Miguel J; Bladé J
    Haematologica; 2006 Jul; 91(7):871-2. PubMed ID: 16818272
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of bortezomib in the treatment of lymphoma.
    Barr P; Fisher R; Friedberg J
    Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis.
    Riccioni R; Senese M; Diverio D; Riti V; Buffolino S; Mariani G; Boe A; Cedrone M; Lo-Coco F; Foà R; Peschle C; Testa U
    Br J Haematol; 2007 Oct; 139(2):194-205. PubMed ID: 17897295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
    Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of proteasome inhibitors in the treatment of patients with multiple myeloma].
    Rukavitsyn OA
    Ter Arkh; 2006; 78(10):40-4. PubMed ID: 17180936
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib in multiple myeloma.
    Meisler AI
    N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
    Lonial S; Richardson PG; San Miguel J; Sonneveld P; Schuster MW; Bladé J; Cavenagh J; Rajkumar SV; Jakubowiak AJ; Esseltine DL; Anderson KC; Harousseau JL
    Br J Haematol; 2008 Oct; 143(2):222-9. PubMed ID: 18713253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib in multiple myeloma.
    Faix JD
    N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14507954
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.